JBM (Healthcare) Limited Debuts on The Main Board of SEHK

HONG KONG SAR – Media OutReach
– 5 February 2021 – JBM (Healthcare)
Limited (“JBM Healthcare” or “Company“, together with its
subsidiaries, the “Group”), a Hong
Kong-based company that markets and distributes branded healthcare products
across Greater China, Southeast Asia and certain other countries, started trading
today on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”)
under stock code 2161.

JBM Healthcare’s diversified brand portfolio comprises a total of 20 principal brands, including 11 third-party brands and 9 own brands.

 

As a subsidiary of Jacobson
Pharma Corporation Limited (“Jacobson Pharma”; Stock Code: 2633), JBM
Healthcare is a unique field player with drug expertise and ethical heritage
that prioritises product efficacy and quality to meet consumers’ healthcare
needs. As a leading healthcare brand operator in Hong Kong, the Group carried a
total of 20 principal brands, including 11 third-party brands and 9 own brands covering
both OTC proprietary medicines and OTC proprietary Chinese medicines. Upon completion of the public listing, Jacobson
Pharma continues to indirectly hold over 50% equity interest in JBM Healthcare
and JBM Healthcare remains as a subsidiary of Jacobson Pharma.

 

Further to the successful listing, the Group will aim at
expanding its product offerings and deepening product penetration in China
through cross-border e-commerce initiatives as a result of the rapid growth of
the PRC cross-border e-commerce market, as well as the rising demand for
overseas healthcare products along with an increasingly structured and formalized
cross-border e-commerce channel in the PRC market. Simultaneously, the Group will
also further expand its portfolio through organic growth and mergers and
acquisitions to maintain its competitive position and ensure its future growth
and success.

 

Leveraging the Group’s
established local business relationships and networks, JBM Healthcare targets
to develop a branded healthcare product sourcing and distribution platform in
Asia through the integration of its regional resources and foothold, strengthening
and expanding its geographical reach in Southeast Asia. In addition, backed by its
extensive market base in Hong Kong, the Group is well poised to unleash the
sales and distribution potential of its Chinese medicine practitioner network.

 

The net proceeds from the Public Offer amounted to approximately HK$10.6
million. The Group will allocate 47.2% of the proceeds to fund portfolio development and brand management of proprietary Chinese
medicines; while 43.4% will be used to pay for the obtaining of additional
distribution rights from third-party brand owners, as part of the strategy to
grow its third-party brand product portfolio. The remaining 9.4 % will be used
to supplement working capital and for general corporate purposes.